Search

You searched for "information"

3398 results found

UKEGS Conference 2025

5 November 2025 -6 November 2025
UKEGS (UK and Éire Glaucoma Society) Conference 2025

LSHTM: Global Eye Health

3 November 2025 -6 November 2025
London School of Hygiene and Tropical Medicine Global Eye Care Short Course
Basics of Vitrectomy book cover image.

Basics of Vitrectomy

3 June 2021 |
This is a book set out over 14 chapters which is designed to be a handbook for beginners embarking on a career in vitreoretinal (VR) surgery or for trainee surgeons on rotation with the VR team. It starts with an...

Second major survey calls for people with sight loss to review ideas for innovation of post diagnostic support for blind and partially sighted people

8 September 2025 | charity, RNIB, survey, sight loss, patient stories
This September the UK’s largest sight loss charity, The Royal National Institute of Blind People (RNIB), is launching the second in a series of major surveys to help map out the future of support for people diagnosed with serious eye...

Ophthalmic surgeon returns to London Marathon after 31 years for Glaucoma UK

30 April 2024 | Glaucoma, charity, event, anniversary, 50th, UK, London, fundraising, i will
Michael Miller, in commemoration of Glaucoma UK's 50th anniversary, has achieved a remarkable feat by completing this year's London Marathon, three decades after he last completed the challenge in 1993, which he also ran in support of the charity.
Ocular Oncology and Pathology cover image.

High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema

1 April 2017 | | EYE - Pathology, EYE - Oncology | Anti-VEGF, Cystoid macular edema, Melanoma, Radiation damage, Radiotherapy, Tumor
The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...

Retinal arteriovenous malformation

1 June 2018 | | EYE - Vitreo-Retinal
A 24-year-old Caucasian girl reported to the eye clinic with the complaint of painless decreased vision in her right eye. She had no history of infectious disease, trauma, systemic malignancy or other systemic complaint. Her best corrected visual acuity was...

Treatment of diabetic macular oedema

1 June 2014 | | EYE - Vitreo-Retinal
Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...

Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity

5 June 2023 |
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...

Quiz Oct/Nov 2022

3 October 2022 | | EYE - General
History An Afro-Caribbean woman, aged 30, with “scleral tattooing” for cosmetic reasons (subconjunctival dye injection), presented with bilateral upper and lower eyelid oedema for one week, and she also had restricted eye movement and blurry vision in her right eye....

Commonwealth nations join forces to prevent blindness from diabetes

1 February 2015 | | EYE - Cataract, EYE - Cornea, EYE - Glaucoma, EYE - Imaging, EYE - Neuro-ophthalmology, EYE - Oculoplastic, EYE - Oncology, EYE - Orbit, EYE - Paediatrics, EYE - Pathology, EYE - Refractive, EYE - Strabismus, EYE - Vitreo-Retinal, EYE - General
More than 70 representatives from 10 Commonwealth countries (in the African, Caribbean and Pacific regions) and Indonesia gathered at a five-day workshop in November 2014 to establish district or national plans to reduce blindness from diabetic retinopathy (DR). The event...

Heidelberg Engineering joins the Collaborative Community on Ophthalmic Innovation (CCOI) through EssilorLuxottica’s Vision Architect membership

26 January 2026 | Contracts & Distributors, Company Profiles
Heidelberg Engineering announced that it is joining the Collaborative Community on Ophthalmic Innovation (CCOI) as part of its parent company EssilorLuxottica’s Vision Architect membership – CCOI’s highest level of industry participation. CCOI is a public–private forum that convenes patients, clinicians,...